Indonesia’s potential wealth in natural resources, as the second-largest country in terms of biodiversity, boasting over 28 thousand species of plants and 2,848 medicinal plants, presents significant opportunities for the development of natural medicine and Indonesia Indigenous Modern Medicine (OMAI) phytopharmaceuticals. Dra. Reri Indriani, Senior Expert Pharmacist and Food Supervisor at BPOM, emphasized the crucial role of regulatory support and oversight in the development

In the 2024 State Budget and Revenue (APBN), President Joko Widodo allocated IDR 186.4 trillion or 5.6 percent for the health sector. One of the primary goals is to reduce the prevalence of stunting in Indonesia to 14 percent by 2024. To accelerate the stunting reduction target of 14 percent by 2024, Dexa Medica collaborated with the National Population and Family Planning Board (BKKBN) to hold am Education and Stunting Intervention for Midviwes program on Friday, October 27,

The President of the Republic of Indonesia (RI) Mr. Joko Widodo appreciated and encouraged the use of Indonesia Indigenous Modern Medicine (OMAI) in the National Health Insurance (JKN). This was conveyed during a visit to the Dexa Group booth with the theme OMAI Fitofarmaka at the Business Matching Exhibition for Increasing the Use of Domestic Production (P3DN) which took place at Istora Gelora Bung Karno (GBK) Senayan, Wednesday, 15 March 2023. During a visit to the Dexa Gro

The Indonesian Pharmaceutical Companies Association (GP Farmasi) held an interactive dialogue entitled “Safe Medicinal Syrups for Children”. It was revealed that the requirement for safe syrup preparations is in accordance with the provisions of the Food and Drug Administration (BPOM). “BPOM in conducting evaluations, in issuing permits, many standards are used both nationally and internationally. What BPOM is doing is international best practice,” said Plt. Director of BPOM

The pharmaceutical business is still working toward independence and health security due to the changes in the market brought on by the pandemic circumstances, the global financial crisis, and the high US Dollar exchange rate against the Rupiah. Dexa Group presented three significant initiatives for pharmaceutical resilience and independence with government assistance. “The nation has to develop resilience and self-sufficiency since its reliance on imports causes it to trembl

The government primarily focuses on developing phytopharmaceuticals to create a system of health resilience and domestic pharmaceutical self-reliance. Launching the Phytopharmaca Formulary and promoting its usage in medical institutions are examples of the government’s commitment to fostering the use of phytopharmaceuticals. The Director General of Pharmaceuticals and Medical Devices at the Indonesian Ministry of Health, Ms. Lucia Rizka Andalusia, said that the government is

With more than 28,000 plant species and 2,848 medicinal plants, Indonesia has the second-highest biodiversity in the world. Its natural resources hold tremendous promise for developing phytopharmaceuticals and herbal medicines, including Indonesia Indigenous Modern Medicine (IIMM). Penny K. Lukito, head of the Food and Drug Supervisory Agency (BPOM), stated that the government prioritizes the creation of natural medicines in all areas. So that the national pharmaceutical indu

Indonesia’s 29th National Family Day (Harganas) was celebrated with the theme “Let’s Prevent Stunting for Stunting-Free Family”. President Joko Widodo (Jokowi) said that the government had appointed the National Population and Family Planning Agency (BKKBN) to reduce the prevalence of stunting to 14% in 2024. Therefore, BKKBN collaborates with several partners, including Dexa Group. “In commemoration of the 29th National Family Day, I invite all the nation’s forces to move fo

The ‘Bangga Buatan Indonesia’ Movement (BBI) is supported by 35 District/City Health Offices in Central Java Province, which provide the Special Allocation Fund (DAK) and the APBD for health expenditure on Indonesian Indigenous Modern Medicines (OMAI). Thie program is not just to comply with Presidential Instruction (Inpres) No. 2 of 2022 but also the awareness of herbal remedies, both those that are still treated traditionally and those that are handled scientifically. The G

According to the Indonesia Nutrition Status Survey (SSGI), in 2021, the prevalence of stunting in Indonesia will be 24.4 percent, a 6.4 percent decrease from 30.8 percent in 2018. To meet the goal of reducing stunting prevalence to 14 percent by 2024, the Population Agency and the National Family Planning (BKKBN) issued an Alert Call for the Mobile Family Assistance Team. They enlisted the help of several partners. Dexa Group, a national pharmaceutical company, is one of the